References
Kucukarslan S. Regulatory concerns with gene therapy and recombinant therapeutic proteins: implications for drug development. Clin Immunother 1994 May; 1(5): 358–68
Whartenby KA, Marrogi AJ, Freeman SM. Gene therapy: clinical potential and relationships to drug treatment. Drugs 1995 Dec; 50(6): 951–8
Afione SA, Conrad CK, Flotte TR. Gene therapy vectors as drug delivery systems. Clin Pharmacokinet 1995 Mar; 28: 181–9
Avalosse B, Dupont F, Burny A. Gene therapy for cancer. Curr Opin Oncol 1995 Jan; 7(1): 94–100
Blaese RM, Culver KW, Miller AD, et al. T lymphocyte-directed gene therapy for ADA SCID: initial trial results after 4 years. Science 1995 Oct; 270: 475–80
Bordignon C, Notarangelo LD, Nobili N, et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 1995 Oct 20; 270: 470–5
Knowles MR, Hohneker KW, Zhou Z, et al. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. NEJM 1995 Sep 28; 333: 823–31
Grossman M, Rader DJ, Muller DWM, et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nature Med 1995 Nov; 1: 1148–54
Rights and permissions
About this article
Cite this article
Gene therapy: potential not yet fulfilled. Drugs Ther. Perspect 7, 6–8 (1996). https://doi.org/10.2165/00042310-199607090-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-199607090-00002